Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart transplantation--Stanford experience.

V A Starnes1, N E Shumway

  • 1Department of Cardiovascular Surgery, Stanford University, CA.

Clinical Transplants
|January 1, 1987
PubMed
Summary

Heart transplantation is now a viable treatment for end-stage heart disease, with survival rates improving significantly. Advancements in immunosuppression and devices like the Novacor LVAD enhance patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two decades of experimental and clinical orthotopic homotransplantation of the heart.

Perspectives in biology and medicine·2015
Same author

Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis.

The Annals of thoracic surgery·2001
Same author

Thoracic transplantation.

World journal of surgery·2000
Same author

Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles.

World journal of surgery·2000
Same author

Thirty years of cardiac transplantation at Stanford university.

The Journal of thoracic and cardiovascular surgery·1999
Same author

Forty years of thoracic transplantation at Stanford.

Transplantation proceedings·1999

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Medical Devices

Background:

  • Heart transplantation has transitioned from experimental to a standard therapy for end-stage heart disease.
  • Significant advancements in immunosuppression and surgical protocols have improved outcomes.
  • The increasing number of heart transplants reflects its growing acceptance and efficacy.

Purpose of the Study:

  • To review the outcomes of heart transplantation at Stanford University.
  • To assess the role of left ventricular assist devices as a bridge to transplantation.
  • To highlight trends and future considerations in cardiac transplantation.

Main Methods:

  • Retrospective analysis of 429 cardiac transplant recipients at Stanford since 1968.
  • Review of immunosuppression protocols, primarily a 3-drug regimen (cyclosporine, azathioprine, prednisone).
  • Evaluation of 6 patients receiving a Novacor left ventricular assist device as a bridge to transplant.

Main Results:

  • Recipient diagnoses included cardiomyopathy (205), coronary artery disease (188), and valvular heart disease (20).
  • One- and 5-year survival rates are 83% and 55%, respectively.
  • Three of four patients bridged with a Novacor LVAD survived post-transplant.

Conclusions:

  • Heart transplantation is a successful therapeutic option for end-stage heart disease.
  • Improved immunosuppression and standardized protocols have driven the rise in transplant numbers.
  • Future challenges include donor allocation and establishing center standards for heart transplantation.

Related Experiment Videos